Recurrence of psoriasis vulgaris accompanied by treatment with C-C chemokine receptor type 4 (CCR4) antibody (mogamulizumab) therapies in a patient with adult T cell leukemia/ lymphoma: Insight into autoinflammatory diseases

Internal Medicine

Volumn 55, Issue 10, 2016, Pages 1345-1349

  Morichika, Kazuho ^a   Tomoyose, Takeaki ^a   Hanashiro, Taeko ^a   Shimabukuro, Natsuki ^a   Tamaki, Keita ^a   Tedokon, Iori ^a   Nishi, Yukiko ^a   Nakachi, Sawako ^a   Karube, Ken Nosuke ^a   Fukushima, Takuya ^a   Katoh, Takeharu ^b   Ohshima, Koichi ^b   Masuzaki, Hiroaki ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adult T cell leukemia lymphoma (ATL); Autoinflammatory disease; C C chemokine receptor type 4 (CCR4); Psoriasis vulgaris; Regulatory T cell (Treg)

Indexed keywords

BECLOMETASONE; CD4 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR4; HEMOGLOBIN; MOGAMULIZUMAB; TRANSCRIPTION FACTOR FOXP3; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; AUTOINFLAMMATORY DISEASE; CASE REPORT; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; LYMPHADENOPATHY; MALAISE; MIDDLE AGED; PHOTOTHERAPY; PSORIASIS VULGARIS; RECURRENT DISEASE; REGULATORY T LYMPHOCYTE; REMISSION; SKIN BIOPSY; T CELL LEUKEMIA; THROMBOCYTE COUNT; CHEMICALLY INDUCED; IMMUNOLOGY; LEUKEMIA-LYMPHOMA, ADULT T-CELL; PSORIASIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MIDDLE AGED; PSORIASIS; RECURRENCE;

EID: 84968732818     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.55.5997     Document Type: Article

References (20)

1. Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemialymphoma: Japan Clinical Oncology Group Study JCOG 9801. J Clin Oncol 25: 5458-5464, 2007.
2. Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 116: 1369-1376, 2010.
3. Yano H, Ishida T, Inagaki A, et al. Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer 120: 2052-2057, 2007.
4. Yoshie O, Fujisawa R, Nakayama T, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 99: 1505-1511, 2002.
5. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 30: 837-842, 2012.
6. Ishida T, Ito A, Sato F, et al. Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci 104: 647-650, 2013.
7. Ozen S, Bilginer Y. A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol 10: 135-147, 2014.
8. Kakeda M, Arock M, Schlapbach C, Yawalkar N. Increased ex pression of heat shock protein 90 in keratinocytes and mast cells in patients with psoriasis. J Am Acad Dermatol 70: 683-690, 2014.
9. Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 9: 3625-3634, 2003.
10. Zheng Y, Rudensky AY. FoxP3 in control of the regulatory T cell lineage. Nat Immunol 8: 457-462, 2007.
11. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 133: 775-787, 2008.
12. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155: 1151-1164, 1995.
13. Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. PNAS 110: 17945-17950, 2013.
14. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 361: 496-509, 2009.
15. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19: 225-234, 2003.
16. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449: 564-569, 2007.
17. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 129: 1339-1350, 2009.
18. + CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 174: 164-173, 2005.
19. Furuhashi T, Saito C, Torii K, et al. Photo(chemo)therapy reduces circulating Th17 cells and restores circulating regulatory T cells in psoriasis. PLoS ONE 8: e54895, 2013.
20. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 441: 235-238, 2006.